Stem Cell And Regenerative Therapy Market Research Insights Global Industry Outlook Shared in Detailed Report, Forecast size 2024 – Daily Science

The global stem cell and regenerative medicines market should grow from $21.8 billion in 2019 to reach $55.0 billion by 2024 at a compound annual growth rate (CAGR) of 20.4% for the period of 2019-2024.

Report Scope:

The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries. The current report offers a detailed analysis of the stem cell and regenerative medicines market.

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

Request for Report Sample:https://www.trendsmarketresearch.com/report/sample/11723

The report details market shares of stem cell and regenerative medicines based on products, application, and geography. Based on product the market is segmented into therapeutic products, cell banking, tools and reagents. The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

28 data tables An overview of global markets for stem cell and regenerative medicines Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 Details of historic background and description of embryonic and adult stem cells Information on stem cell banking and stem cell research A look at the growing research & development activities in regenerative medicine Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Summary

Make an Inquiry before Buying:https://www.trendsmarketresearch.com/checkout/11723/Single

The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024. Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

In the global market, North America held the highest market share in 2018. The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period. The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study

Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications. New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future. The biopharmaceutical companies are investing significantly in cell-based therapeutics. The government organizations are funding research and development activities related to stem cell research. These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments. The market is impacted through adoption of stem cell therapy. The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.

Request for Report Discount:https://www.trendsmarketresearch.com/report/discount/11723

Link:
Stem Cell And Regenerative Therapy Market Research Insights Global Industry Outlook Shared in Detailed Report, Forecast size 2024 - Daily Science

Analyzing CRYO-CELL International (OTCMKTS:CCEL) and Harsco (OTCMKTS:HSC) – Redmond Register

CRYO-CELL International (OTCMKTS:CCEL) and Harsco (NYSE:HSC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Valuation and Earnings

This table compares CRYO-CELL International and Harscos revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a summary of current ratings and recommmendations for CRYO-CELL International and Harsco, as provided by MarketBeat.com.

Harsco has a consensus price target of $26.67, suggesting a potential upside of 325.99%. Given Harscos higher probable upside, analysts clearly believe Harsco is more favorable than CRYO-CELL International.

Volatility & Risk

CRYO-CELL International has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500. Comparatively, Harsco has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500.

Profitability

This table compares CRYO-CELL International and Harscos net margins, return on equity and return on assets.

Institutional & Insider Ownership

0.3% of CRYO-CELL International shares are owned by institutional investors. Comparatively, 92.2% of Harsco shares are owned by institutional investors. 54.0% of CRYO-CELL International shares are owned by company insiders. Comparatively, 1.8% of Harsco shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Harsco beats CRYO-CELL International on 8 of the 12 factors compared between the two stocks.

CRYO-CELL International Company Profile

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue specimens worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was founded in 1989 and is headquartered in Oldsmar, Florida.

Harsco Company Profile

Harsco Corporation provides industrial services and engineered products worldwide. The company operates in three segments: Harsco Metals & Minerals, Harsco Industrial, and Harsco Rail. The Harsco Metals & Minerals segment provides on-site services of material logistics, product quality improvement, and resource recovery for iron, steel, and metals manufacturing; and value added environmental solutions for industrial co-products, as well as produces industrial abrasives and roofing granules. The Harsco Industrial segment manufactures and supplies custom-engineered and manufactured air-cooled heat exchangers for the natural gas, natural gas processing, and petrochemical industries; industrial grating products, such as metal bar grating configurations for industrial flooring, and safety and security applications in the energy, paper, chemical, refining, and processing industries. It also offers heat transfer products, such as boilers and water heaters for commercial and institutional applications; and high-security fencing products. The Harsco Rail segment designs and manufactures safety systems for transportation and industrial applications; and equipment, after-market parts, and services for the maintenance, repair, and construction of railway track. It serves private and government-owned railroads, and urban mass transit systems. Harsco Corporation was founded in 1853 and is headquartered in Camp Hill, Pennsylvania.

Receive News & Ratings for CRYO-CELL International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRYO-CELL International and related companies with MarketBeat.com's FREE daily email newsletter.

Original post:
Analyzing CRYO-CELL International (OTCMKTS:CCEL) and Harsco (OTCMKTS:HSC) - Redmond Register

15 Good News Stories To Tackle The COVID-19 Sadness – IFLScience

For Earth, bleak times lay ahead. TheCOVID-19 diseaseis known to cause respiratory illness and fever, but some extra symptoms sweeping across the globe right now seem to be stress, fear, and anxiety. To provide some light relief in these dark times, weve collated 15 of our favorite good news stories to remind you that not everything is awful. Hold tight everybody, 2021 will come eventually.

The Super Pink Moon is comingYou might be stuck at home as part of your self-isolation, but luckily the night sky is about to put on quite a show as April sees the return of the Super Pink Moon. Full moons happen every month and were given different names by the Native Americans to map out the year based on significant events that ran in tandem with the occurrence of a full Moon. Aprils is known as the pink moon because it appeared at the same time as pink spring flowers. This Aprils will be a Super Pink Moon as it is the second supermoon of the year, a term used to describe the slightly enlarged appearance of the Moon as its fully illuminated by the Sun due to Earths position between the two. Quarantine or no, if you've got access to a window you should be able to catch sight of this beauty on April 7 and when you do, think of all the other people looking up at the same moon. Self isolation doesn't mean you're alone.

Mice have been cured of diabetesAn astonishing discovery at the Washington University School of Medicine in St. Louis has revealed that human stem cells could be successfully engineered to cure diabetes in mice, offering an avenue of hope for the treatment of this debilitating disease. They used human pluripotent stem cells, cells that have the capacity to become any cell in the body, to create insulin-producing pancreatic beta cells. The engineered stem cells supplemented the diabetic mices inability to produce insulin, curing them of the disease for 9 months to a year before relapse occurred.

Theres a new green fuel in townHydrogen fuel was fast shaping up to be a hopeful route for a zero-emissions means of running things, but its costly production in terms of energy was affecting hopes for it being a sustainable resource. A team in Tokyo has now managed to refine the process to yield 25 times more hydrogen than previous methods all while using thrifty ingredients including light and a specific kind of rust. Combined with all the solar power breakthroughs currently occurring, green energy is on the up.

A crash course in what not to do, according to one Stanford University psychologist.

Babies love baby talkEven if it makes your skin crawl to hear adults cooing over little uns, it turns out babies across the globe are universally partial to baby talk. The news comes fromStanford psychologist Michael Frank who led the largeststudyto date looking at how the different ways adults speak is received by babies across the world. While all babies were fans, older babies liked it best and even showed a preference for baby talk in their native language as they likely recognized it most even if they couldnt speak it yet. The overall winner was oohs and coos, so think twice before scorning your new-parent friends for embarrassing you in public the babies have spoken.

Important change in the winds for HIV treatmentShortly after a UK man became the second person cured of HIV a fantastic breakthrough in the treatment of this once devastating disease theres more good news in the UK as PrEP, a preventative drug that prevents HIV infection, will finally be available nationwide on the NHS having already been made available in Scotland. After a 3-year study involving 20,000 participants, the drug will be made available to those at higher risk of exposure from April. PrEP is already available in the US and you can find PrEP providers near you here.

-

Plasters finally take a step towards racial inclusivityMajor UK superstore Tesco has taken the long-awaited step to introduce skin tone diversity into their range of bandaids. Previously, widely available bandaids, or plasters in the UK, have mainly catered to Caucasian individuals and the racial oversight was brought to light by a moving Tweet from Domonique Apollon in April 2019 after he wore a bandaid suitable for his skin tone for the first time. Longtime readers of Malorie Blackman's literary series Noughts and Crosseswill appreciate this poignant detail becoming a reality, as will those watching the current BBC dramatization available to watch via iPlayer in the US (excellent for those self-isolating).

Universal flu vaccine passes integral stageWatchers of the Pandemic documentary on Netflix (we wouldnt recommend catching up now if you missed it) may remember the plight of flu-fighting epidemiologists as the constantly shape-shifting nature of influenza meant strains were annually moving beyond existing vaccinations. Now, a universal vaccine is becoming a reality as for the first time a vaccine, called FLU-v, has been developed that can induce immune responses that last at least six months. Phase I and II of the clinical trial have been approved meaning its safety for use in human subjects and we hotly await what comes next for the groundbreaking vaccine.

Top marks for lights out in dark sky nationSometimes a bit of darkness can be a good thing, and when it comes to nighttime, the tiny South Pacific island of Niue tops the charts. The International Dark-Sky Association (IDA) is a non-profit working to protect our most precious natural spaces from light pollution, and this year chose Niue as the first entire country ever to be accredited as a Dark Sky Place. This classification recognizes responsible lighting policies that preserve the natural darkness of nighttime carrying with it endless benefits for the biological cycles of animals, plants and humans.

-

People hating on National Parks created beautiful artIn a glimmering example of you cant please everybody, artist Amber Share decided to take some of the best worst reviews of National Parks in America and turn them intotourism posters, showing that we can still make something funny in the face of people's negativity. You can see the whole collection on her Instagram account @subparparks, but a personal favorite has to be the above magnificent minimization of Yellowstone.

CRISPR may hold the key for curing genetic blindnessSurgeons at Oregon Health & Science Institute have attempted to use gene hacking to cure Leber congenital amaurosis, a genetic condition that leads to the onset of blindness in early childhood. By directly gene editing within the patients eye, researchers hope to ...take people who are essentially blind and make them see," according to researchers.

The Arctic seed vault in Svalbard is thrivingLast month saw an enormous glut of 60,000 seed samples added to the ever-growing collecting in the Svalbard Global Seed Vault. Tucked beneath a mountain in Norway's Svalbard archipelago, the initiative began with hopes to create a Noahs ark for plant diversity to protect our green spaces should a global catastrophe occur up top. The collection now includes 1.05 million seed varieties including the first-ever donation from an indigenous US tribe. Nicknamed the "Doomsday vault", we may need it sooner than thought.

Sea sponges can sneeze, and the footage is amazingThe aah and choo of asneezing sea spongehas been caught on camera for the first time and the recording is hilarious. Stumbled upon almost by accident, the discovery came about while researchers were observing sea cucumbers and sea urchins sniffing the sea floor. The video shows the two-part sneeze of a tulip-shaped sponge as it expands before contracting, expelling particles as it goes. Researchers arent yet sure what the sneezes are in response to. Lets hope its not a case ofthe suds.

Vernal equinox brings early springThe times might be dark but for the Northern hemisphere, the days wont be, as spring arrives on March 19, the earliest date in 124 years. The variation in the date is the result of leap years and daylight savings time. It should be noted this is the astronomical definition of spring, which refers specifically to the position of Earth's orbit in relation to the Sun, so perhaps dont expect to hear a gay little spring song in your garden just yet.

Its possible some dinosaurs could GLOW IN THE DARKA titillating discovery published in the journal Historical Biology recently revealed that some dinosaurs may have glowed in the dark thanks to ultraviolet fluorescing feathers and horns. Many extant bird species are tetrachromats, defined by a fourth cone in their retina that means they can see the UV spectrum. Co-author Jamie Dunning's work on the photoluminescence of puffin beaks under UV light inspired the questions, could dinosaurs have this too? We'd like the answer to be yes, please. The only thing cooler than dinosaurs is glow-in-the-dark dinosaurs.

If you need more positivity in your life right now, take a look at these ingenious social distancing moments from around the world that will restore your faith in humanity.

More:
15 Good News Stories To Tackle The COVID-19 Sadness - IFLScience

New Research On Brain Structure Highlights Cells Linked To Alzheimer’s And Autism – BioSpace

New insights into the architecture of the brain have been revealed by scientists at the Wellcome Sanger Institute, the Wellcome-MRC Cambridge Stem Cell Institute and their collaborators. The researchers discovered that cells in the cerebral cortex of mice, called astrocytes, are more diverse than previously thought, with distinct layers of astrocytes across the cerebral cortex that provide the strongest evidence to date of their specialization across the brain.

Published today (16 March) in Nature Neuroscience, the most in-depth study of its kind is set to change the way we think about the brain and the role of cells such as astrocytes. This knowledge will have with implications for the study of neurological disorders, such as Alzheimers, multiple sclerosis and autism.

In the past 20 years, research has shown glial cells to be key players in brain development and function, as well as promising targets for better understanding neurological disorders. Alzheimers causes around two thirds of dementia cases in the UK, which affects around 850,000 individuals at present*. MS is a neurological disorder that affects the central nervous system and impacts around 100,000 people in the UK**. Autism affects around one in every hundred people in the UK***.

Glial comes from the Greek word for glue or putty. At one time, glial cells were thought of as 'brain putty' functionally similar, passive cells whose only function was to fill the space around the all important neurons. However, new studies are showing their critical importance in regulating neuron functions^. Astrocytes are a type of glial cell, so called because of their star-shaped structure^^.

Despite the wealth of knowledge on neuronal function and the organisation of neurons into layers, prior to this study there had been little investigation into whether glial cells across different layers showed different cellular properties. To answer this question, the researchers developed a new methodological approach to provide a more detailed view of the organisation of astrocytes than ever before.

Nucleic acid imaging was carried out on mouse and human brain samples at the University of Cambridge to map how new genes are expressed within tissue. These maps were combined with single cell genomic data at the Wellcome Sanger Institute to extend the molecular description of astrocytes. These data sets were then combined to create a three-dimensional, high-resolution picture of astrocytes in the cerebral cortex.

The team discovered that astrocytes are not uniform as previously thought, but take distinct molecular forms depending on their location in the cerebral cortex. They found that astrocytes are also organised into multiple layers, but that the boundaries of astrocyte layers are not identical to the neuronal layers. Instead, astrocyte layers have less sharply defined edges and overlap the neuronal layers.

Dr Omer Bayraktar, Group Leader at the Wellcome Sanger Institute, said: The discovery that astrocytes are organised into layers that are similar, but not identical to, neuronal layers redefines our view of the structure of the mammalian brain. The structure of the cerebral cortex can no longer simply be seen as the structure of neurons. If you want to properly understand how our brains work, you have to consider how astrocytes are organised and what role they play.

As well as increasing our understanding of brain biology, the findings will have implications for the study and treatment of human neurological disorders. Over the past decade glial cells, rather than neurons, have been heavily implicated in diseases such as Alzheimers and multiple sclerosis.

Professor David Rowitch, senior author of the study and Head of Paediatrics at the University of Cambridge, said: This study shows that the cortical architecture is more complex than previously thought. It provides a basis to begin to understand the precise roles played by astrocytes, and how they are involved in human neurodevelopmental and neurodegenerative diseases.

ENDS

Contact details:Dr Matthew MidgleyPress OfficeWellcome Sanger InstituteCambridge, CB10 1SAPhone: 01223 494856Email: press.office@sanger.ac.uk

Notes to Editors:

In the cerebral cortex of the mammalian brain, neurons are the cells responsible for transmitting information throughout the body. It has long been recognised that the 10-14 billion neurons of the human cerebral cortex are organised into six layers, with distinct populations of neurons in each layer that correspond to their function https://www.dartmouth.edu/~rswenson/NeuroSci/chapter_11.html

* More information on Alzheimers disease can be found here: https://www.alzheimersresearchuk.org/about-dementia/types-of-dementia/alzheimers-disease/about/

**More information about MS can be found here: https://www.mssociety.org.uk/about-ms/what-is-ms

*** More Information on autism is available from the National Autistic Society: https://www.autism.org.uk/about/what-is/asd.aspx

^ An overview of the changing status of glial cells is available at: https://blogs.scientificamerican.com/brainwaves/know-your-neurons-meet-the-glia/

^^ Only half of the cells in the human cerebral cortex are neurons, the other half are glial cells, of which astrocytes are a type. The molecular signals that astrocytes provide are essential for forming synapses between neurons. They regulate synapse formation in the developing brain, as well as refining synapses in the maturing brain 'pruning' extra synapses to sculpt neuronal networks.

Publication:

Omer Ali Bayraktar, Theresa Bartels and Staffan Holmqvist et al. (2020). Astrocyte layers in the mammalian cerebral cortex revealed by a single-cell in situ transcriptomic map. Nature Neuroscience. https://doi.org/10.1038/s41593-020-0602-1

Funding:

The study was supported by the Dr Miriam and Sheldon G. Adelson Medical Research Foundation, National Institute of Health (1R01 MH109912; P01NS08351), NINDS Informatics Center for Neurogenetics and Neurogenomics (P30 NS062691), Wellcome and the European Research Council (281961).

Selected websites:

Wellcome - MRC Cambridge Stem Cell InstituteThe Wellcome - MRC Cambridge Stem Cell Institute is a world-leading centre for stem cell research with a mission to transform human health through a deep understanding of normal and pathological stem cell behaviour. Bringing together biological, clinical and physical scientists operating across a range of tissue types and at multiple scales, we explore the commonalities and differences in stem cell biology in a cohesive and inter-disciplinary manner. In 2019, we relocated to a new purpose-built home on the Cambridge Biomedical Campus. Housing over 350 researchers, including a critical mass of clinician scientists, the Institute integrates with neighbouring disease-focused research institutes and also serves as a hub for the wider stem cell community in Cambridge. https://www.stemcells.cam.ac.uk/

About the University of Cambridge

The mission of the University of Cambridge is to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence. To date, 107 affiliates of the University have won the Nobel Prize.

Founded in 1209, the University comprises 31 autonomous Colleges, which admit undergraduates and provide small-group tuition, and 150 departments, faculties and institutions. Cambridge is a global university. Its 19,000 student body includes 3,700 international students from 120 countries. Cambridge researchers collaborate with colleagues worldwide, and the University has established larger-scale partnerships in Asia, Africa and America.

The University sits at the heart of the Cambridge cluster, which employs 60,000 people and has in excess of 12 billion in turnover generated annually by the 4,700 knowledge-intensive firms in and around the city. The city publishes 341 patents per 100,000 residents. http://www.cam.ac.uk

The Wellcome Sanger InstituteThe Wellcome Sanger Institute is a world leading genomics research centre. We undertake large-scale research that forms the foundations of knowledge in biology and medicine. We are open and collaborative; our data, results, tools and technologies are shared across the globe to advance science. Our ambition is vast we take on projects that are not possible anywhere else. We use the power of genome sequencing to understand and harness the information in DNA. Funded by Wellcome, we have the freedom and support to push the boundaries of genomics. Our findings are used to improve health and to understand life on Earth. Find out more at http://www.sanger.ac.uk or follow us on Twitter, Facebook, LinkedIn and on our Blog.

About WellcomeWellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation. https://wellcome.ac.uk

See original here:
New Research On Brain Structure Highlights Cells Linked To Alzheimer's And Autism - BioSpace

Rethinking the Definition of Cure as Patients With HIV Wait – Medscape

BOSTON A year ago, a man living with HIV walked into the exam room of Maile Young Karris, MD, from the UC San Diego Medical Center. He had seen on the news that there was a cure for HIV, and asked Karris: "How can I get it?"

Karris, who specializes in HIV primary care, explained that although one man then known as the London patient had been off medication for 18 months and remained in remission, that cure, if it were really a cure, was not available to him or, really, to any other patient with HIV.

"I'm often very hopeful. I believe we will get there," she told Medscape Medical News. "We're sort of just one scientific advance away."

But back then, she had to explain that the London patient, like the Berlin patient before him, had to get to the point of almost dying from cancer before the stem cell transplant that changed his immune system was even a possibility, and that both men had undergone a painful and invasive immunologic makeover.

So when it was reported at the virtual Conference on Retroviruses and Opportunistic Infections (CROI) 2020 that the London patient, now identified as Adam Castillejo, is still in remission a year later, even the researcher who performed the transplant was willing to say it's probably a cure.

But that likely won't change the way Karris or other HIV providers care for patients.

When Ravindra Gupta, MD, from University College London, presented the case of the London patient at CROI 2019, he was very careful to say "remission", not "cure".

But when he presented the case at CROI this year, he called it a cure, and he and his colleagues, in their report of the evidence published in the LancetHIV, state that "these findings probably represent the second recorded HIV-1 cure."

In May 2016, Castillejo received a stem cell transplant to treat stage4 Hodgkin's lymphoma, a non-AIDS-defining cancer. That transplant, like the one that Timothy Ray Brown, the so-called Berlin patient, received contained stem cells with two genetic mutations that remove the CCR5 receptor from the surface of the T-cell. Without that receptor, most HIV strains can't invade cells and, therefore, can't proliferate.

When Gupta presented preliminary findings last year, Castillejo had only been off HIV treatment for 18 months and was nearly 2 years out from his transplant. Back then, the team only took blood samples, but they showed that HIV wasn't present.

Then, just last month, samples from Castillejo including blood, plasma, semen, and tissue from his rectum, cecum, sigmoid colon and terminal ileum, and auxiliary lymph nodes were subjected to DNA, RNA, and other testing to see if the virus really was gone.

Although Castillejo's T-cell count is starting to approach where it had been before the transplant, there is no evidence that HIV is replicating in the blood, semen, or tissue samples tested, Gupta reported.

There were remnants of HIV genetic sequences in T-cells and in lymph node samples, though.

"Those can be regarded as so-called fossils," artifacts of past infection, not proof that HIV was still alive in his system, the researchers explain in the published report.

The findings are exciting, said Sharon Lewin, MBBS, PhD, from the Peter Doherty Institute for Infection and Immunity at the University of Melbourne in Australia, who was not involved in the study.

"It makes me think about a new definition of cure," she told Medscape Medical News. It's "the idea that clearing intact virus is what we're doing. And people may well have defective remnants of the virus, but that defective remnant can't replicate."

Of course, this is all still conjecture, she acknowledged. No one knows how long someone has to follow a person like Brown or Castillejo to know for sure that it will never come back. But she seems reassured that Castillejo had made it past the 27-month mark, which is when the viral load of the Mississippi baby rebounded.

When Gupta presented data on the London patient last year, "it was electric," said Rajesh Gandhi, MD, from Massachusetts General Hospital in Boston. "I think most of us remember where we were."

So it's probably not a surprise that people living with HIV were also electrified. It was a topic that popped up in many exam rooms, which some clinicians blamed on newspapers headlines such as "HIV Is Reported Cured in a Second Patient."

And even for patients who weren't asking directly for a stem cell transplant, the question of cure was urgent for many of them.

"I think most of my patients weren't thinking that it is so easy that they want to go through the rigors of chemotherapy," Gandhi told Medscape Medical News. But "people have definitely come in to my clinic asking: 'What type of cure research are you doing?'"

Gandhi said he directs patients back to what does work: a single pill a day to control HIV.

Right now, Gandhi has a patient who has had both cancer and HIV. The cancer is now gone, but the HIV remains. The patient shared his cancer diagnosis with family but still hasn't disclosed his HIV status.

"He could get all the support from his family around cancer, but he never could share his HIV diagnosis," Gandhi said. "I think this is what motivates people to ask about the London patient and the Berlin patient."

People are still afraid of HIV.

Karris has noticed the same thing. Not long ago, a woman came to the clinic and reported that her partner had pulled a knife on her.

"He'd found her HIV meds in her purse and looked it up," Karris explained. "He took a knife to her because she didn't disclose. He said he was going to cut off her fingertips."

The woman has a suppressed viral load, meaning she can't transmit the virus to her partner. California changed its criminal code in 2017 to make HIV nondisclosure a misdemeanor instead of a felony.

"People are still afraid of HIV," Karris said. "Some people hate the idea that they have HIV. This is one reason people stop taking medicine. They tell me: 'I hate coming here. I don't feel sick. And when I come to the clinic, I'm reminded I'm sick. When I take my meds, I'm reminded I'm sick'."

For patients who feel that way, she has three things to offer. One is the concept of undetectable equals untransmittable, meaning that they aren't putting the people they care about in the position to acquire HIV. That's been transformational for many patients, she said.

The second is that new HIV medications are coming soon that will be taken every month or every other month. "That seems helpful for them," she said. "They like the idea of coming in once a month. Then they don't have to think about it every day."

And finally, she said, she's excited to share a new tidbit, also presented at this year's CROI, that people who have CD4 a T-cell count of at least 500cells/mm3 when they start taking medication now have an average lifespan just 3 years less than those in the general public.

"The gap is closing between people living with HIV and those without," she said. "I try to communicate that. It can be mind-blowing for them, to see that they could live as long as anyone else."

Conference on Retroviruses and Opportunistic Infections (CROI) 2020: Abstract346. Presented March10, 2020.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Read this article:
Rethinking the Definition of Cure as Patients With HIV Wait - Medscape

Cancer and COVID-19: What you should know – Newswise

Newswise The number of COVID-19 cases are expected to continue to grow across the globe in the upcoming months and that means more people will have to take extra measures to help protect themselves and reduce the transmission of the disease. This is particularly important for people with cancer, whose immune systems have often been weakened by their cancer treatments.

But does that mean people with cancer should stockpile hand sanitizer and face masks?

Oncologists Gary Schiller, MD, and Joshua Sasine, MD, PhD, help explain what cancer patients need to know about COVID-19.

Dr. Schiller is a professor of hematology/oncology at the David Geffen School of Medicine at UCLA and director of the hematological malignancies/stem cell transplantation unit, and Dr. Sasine is an assistant professor of medicine and director of the CAR T cell program at the UCLA Jonsson Comprehensive Cancer Center.

Which cancer patients should be concerned about coronavirus?

Sasine: The patients most at risk are those with bone marrow cancers or who have had a bone marrow transplant within the last 12 months. If patients have cancer and are on active chemotherapy, they are also at a higher risk than the general population. This is especially true if they are over the age of 60.

Schiller: Bone marrow transplant recipients who received bone marrow from other people are the most immunocompromised patients we take care of and the group at greatest risk for sustaining a life-threatening complication from an infection.

What does it mean to have a compromised immune system?

Sasine: The body's white blood cells normally clear out infections, like bacteria, viruses, and fungi. When the cells have either decreased in number, function, or both, the immune system is compromised. This can be due to having cancer, HIV, getting chemotherapy, and many other situations. This means that a person is more likely than others to contract an infection and the infection is likely to do more harm than average. It might also last longer.

Are there precautions cancer patients should be taking?

Schiller: Patients who are immunocompromised need to be wary of going into crowds, should maintain good hand washing techniques and should stay away from individuals who have a cough.

Sasine: For most events, canceling plans is ideal. However, sometimes one must weigh the risks and benefits. If there is a very important event (son or daughter is getting married, etc.) this might be a risk worth taking.

Should cancer patients delay travel plans?

Schiller: For patients with malignancies of the blood and bone marrow, and patients who had bone marrow transplants, I absolutely tell them to delay travel. Dont travel right now.

Is it safe for patients to come to the hospital and clinics for treatment?

Schiller: Yes. Weve been working to develop better isolation procedures and policies to isolate the potentially sick patients from our immunocompromised patients. For example, bringing the potentially sick patients in through a different entrance to isolate them in the waiting room and put them in an isolation room for evaluation.

Should patients be wearing a mask or stockpile hand sanitizer?

Schiller: A mask is not sufficient protection and were concerned that if you wear a mask, especially one that is insufficiently protective, then you have a false sense of security and you may put yourself in a position that might compromise your safety. In regards to hand sanitizer, I would like my patients to stockpile on soap and water. That would be more effective than using hand sanitizer repeatedly.

Link:
Cancer and COVID-19: What you should know - Newswise

Dr. Michael Everest: The Philanthropist With Undying Passion In Improving Medical Training And Research Programs Globally – Yahoo Finance

Los Angeles, CA, March 13, 2020 (GLOBE NEWSWIRE) -- Dr. Michael Everest is known for his life-changing efforts in supporting initiatives on medical education. He is an American Indian doctor. He faithfully allocates millions of dollars to get solutions to the leading health challenges the world faces through his Everest foundation, a nonprofit global organization that he serves as the chairman. The foundation is named after his father, who strongly advocated for education and believed that medical education should be one of the key focuses in every country. One of the foundation's programs, the Everest scholars, connects medical students and graduates from all over the world to top players in the health sector, such as teaching hospitals, and top-rated medical schools in the United States. Michael Everest seeks to advance medical innovation and philanthropic methods in medical research.

Some of the research areas funded by the organization include nanotechnology and stem cell technology. Still, Dr. Michael Everest has made significant contributions to stem cell technology, which has the capability of treating cancer, stroke, spinal injuries, and Alzheimer's disease. He sponsored the 5k walk/run. All the participants of the walk were wheelchairs users who have spinal injuries. Michael Everest formed a partnership with the Bronx VA exoskeleton and science research department, where he funded one of their stem technology projects. The project has already started to bear fruits. Several people who couldn't walk due to spinal injuries can now walk comfortably. Undoubtedly, such projects are life-changing. He also sponsors such medical events every year.

Dr. Michael Everest holds a strong belief that medical research initiatives are paramount for people from all parts of the world. For this reason, several medical trainees in the Keck School of medicine have benefitted mainly from his foundation. Dr. Michael gifted the medical school with $1m. The gift has backed up research in the institution. The donation has been of much help in the otolaryngology department, which researches the head and neck. The contribution will also enable the institution to carry out advanced research for years to come. Part of it will also benefit the children's hospital of Los Angeles, which has some connections with the Keck School of medicine.

Story continues

Importantly, Dr. Michael Everest has played a significant role in the promotion of medical initiatives in third world countries. Michael Everest makes donations to community-based hospitals in third world countries, which entirely rely on their governments for funding. The contributions enable the hospitals to take necessary research, benefitting the whole community. Through his foundation, he has sponsored quite a good number of hospitals in those countries. He understand s that in most third world-class countries, medical schools offer science training on basic levels, as they cannot afford state of the art research facilities. To solve the problem of half-baked medicine graduates, Michael Everest sponsors the graduates so that they can acquire the necessary research training.

One of his recent initiatives involves backing up pathology training for medical graduates from different parts of the world. True to his words, Dr. Michael Everest donated $500 000 to the University of California. Other institutions that have benefitted from the Everest foundation include the New York medical school, the University of Texas, Stanford University, and many other higher learning institutions. The sponsorships are in the form of residency fellowships, grants, research fellowships, and gifts.

Michael Everest's mission is to advance medical research on a global level. He believes that medical innovation, the advancement of research equipment and methods will be of benefit not only to the current generations but to the coming generations.

Contact@michaeleverest.com

Excerpt from:
Dr. Michael Everest: The Philanthropist With Undying Passion In Improving Medical Training And Research Programs Globally - Yahoo Finance

Human Embryonic Stem Cell (hESC) Market Set to Record Exponential Growth by 2026 with Top Key Players- Astellas Institute of Regenerative Medicine…

Human Embryonic Stem Cell (hESC) Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis. It also provides market information in terms of development and its capacities.

Get Sample Copy (including Full TOC) of this report @:

http://www.a2zmarketresearch.com/sample?reportId=230230

Some of the Top companies Influencing in this Market includes: Astellas Institute of Regenerative Medicine (US), Asterias Biotherapeutics, Inc. (US), BD Biosciences (US), Cell Cure Neurosciences Ltd. (Israel), Cellular Dynamics International (US), GE Healthcare (UK), MilliporeSigma (US), PerkinElmer, Inc. (US), Reliance Life Sciences Ltd. (India), Research & Diagnostics Systems, Inc. (US), SABiosciences Corp. (US), STEMCELL Technologies, Inc. (Canada), Stemina Biomarker Discovery, Inc. (US), Takara Bio, Inc. (Japan), TATAA Biocenter AB (Sweden), Thermo Fisher Scientific, Inc. (US), UK Stem Cell Bank (UK), ViaCyte, Inc. (US), Vitrolife AB (Sweden).

This report provides a detailed and analytical look at the various companies that are working to achieve a high market share in the global Human Embryonic Stem Cell (hESC) market. Data is provided for the top and fastest growing segments. This report implements a balanced mix of primary and secondary research methodologies for analysis. Markets are categorized according to key criteria. To this end, the report includes a section dedicated to the company profile. This report will help you identify your needs, discover problem areas, discover better opportunities, and help all your organizations primary leadership processes. You can ensure the performance of your public relations efforts and monitor customer objections to stay one step ahead and limit losses.

Global Human Embryonic Stem Cell (hESC) Market Detail Segmentation:

Segmentation by Type:

Totipotent Stem CellPluripotent Stem CellUnipotent Stem Cell

Segmentation by Application:

ResearchClinical TrialsOthers

Segmentation by Region:

North America Country (United States, Canada)South AmericaAsia Country (China, Japan, India, Korea)Europe Country (Germany, UK, France, Italy)Other Country (Middle East, Africa, GCC)

Get Upto 25% Discount on first Purchase of this report @:

http://www.a2zmarketresearch.com/discount?reportId=230230

Reasons to Purchase Global Human Embryonic Stem Cell (hESC) Market Report:

Have Query! Ask to Experts @:

http://www.a2zmarketresearch.com/enquiry?reportId=230230

Table of Content

Global Human Embryonic Stem Cell (hESC) Market Report 2020 Growth, Trend and Forecast to 2027

Chapter 1 Human Embryonic Stem Cell (hESC) Market Overview

Chapter 2 Global Economic Impact on Human Embryonic Stem Cell (hESC) Industry

Chapter 3 Global Human Embryonic Stem Cell (hESC) Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region (2014-2020)

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions (2014-2020)

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Human Embryonic Stem Cell (hESC) Market Forecast (2020-2027)

Chapter 13 Appendix

If you have any special requirements, please let us know and we will offer you the report as you want.

Post Views: 102

Original post:
Human Embryonic Stem Cell (hESC) Market Set to Record Exponential Growth by 2026 with Top Key Players- Astellas Institute of Regenerative Medicine...

Lupus can be difficult to diagnose because its symptoms mimic those of other illnesses – PhillyVoice.com

When you are not feeling well, all you want to do is pinpoint why and get proper treatment. For patients with lupus, however, the journey to a correct diagnosis can be especially frustrating.

An estimated 1.5 million people in the U.S. are living with lupus, an autoimmune disease that causes inflammation and tissue damage in the joints, skin, brain, lungs, kidneys and blood vessels.

Dr. Roberto Caricchio, director of the Temple Lupus Program at Temple University Hospital, told PhillyVoice that the biggest challenge in diagnosing lupus is connecting the patient with someone who understands the different ways lupus can affect the body.

So how does it affect the body? He explained, "We have a wonderful immune system able to distinguish ourselves from bacteria, viruses, etc. With an autoimmune disease like lupus, however, the body is not able to tell the difference and attacks itself.

"It is like having a chronic infection but against yourself. Why is that? We don't know. There is some genetic predisposition. There are about 150 abnormal genes, but not all lupus patients have them. We know that women are more prone 90% of people with lupus are women and that the sun can be a trigger, but we only have bits and pieces of the puzzle, not the whole picture," he said.

"We are actually making more progress treating the disease than understanding it."

Women of African American, Hispanic, Asian and Native American descents are at the most risk for lupus. Environmental factors, viruses and infections can also be triggers. Epigenetics, which are changes in chromosomes, is another possible cause.

Lupus is often referred to as the great imitator because its symptoms mimic those of many other illnesses. Lupus symptoms also tend to wax and wane, further complicating the diagnosis process.

According to the Lupus Foundation of America, it takes an average of nearly six years for people with lupus to be diagnosed after they first start to experience symptoms. In a survey of lupus patients, 63% had received incorrect diagnoses at first, and more than half had to see four or more different specialists before the right diagnosis was found.

There are four different types of lupus: systemic lupus erythematosus, cutaneous lupus, neonatal lupus and drug-induced lupus.

"Systemic Lupus Erythematosus can manifest into a diverse range of symptoms and only a lupus expert can recognize the patterns of manifestation," Caricchio said.

Symptoms can include joint pain and swelling, skin rash, fever, fatigue and weight loss. Some of these are constitutional symptoms, meaning that they are not disease specific, complicating the diagnosis process.

Caricchio added that many lupus patients may only have kidney problems or shortness of breath from fluid on their lungs. Others will just have fluid on the heart called pericardial effusion.

One telltale sign of lupus is a facial rash resembling butterfly wings that spread across both cheeks.

Systemic Lupus Erythematosus, orSLE, affects many parts of the body, while cutaneous lupus causes rashes or lesions on the skin, most often after being exposed to sunlight.

Neonatal lupus is a form of lupus that occurs when a mother with SLE passes autoantibodies to her baby, which are mistakenly attacked by the child's immune system. Normally any skin, liver and blood problems resolve within six months. However, if the child develops a congenital heart block, a pacemaker might be needed.

To diagnose lupus, one's doctor will most likely order blood tests for certain auto-antibodies, as well as skin and kidney biopsies, depending on the symptoms.

The tests shouldn't be ordered until the clinical evaluation points to lupus,Caricchio explained,because some people will test positive without actually having the disease.

Treatment of lupus tends to be multidisciplinary because it depends on the parts of the body affected. Since there is currently no cure, the goal is to prevent or treat flare up of symptoms, prevent or reduce damage to affected joints or organs, reduce swelling and pain and suppress an overactive immune system.

Common medicationsprescribed to treat lupus include corticosteroids, antimalarials, biologics, immunosuppressive drugs like cyclophosphamide andnon-steroidal, anti-inflammatory drugs or NSAIDS.

Most lupus patients should take the malaria medication hydroxychloroquine,Caricchio said,because it can ease joint pain and swelling and skin rash.

"Level of treatment changes depending on spectrum of severity," he said. "We are very aggressive when needed, and when a flare stops, then we taper off the medicine."

Asked if eating a special diet can help ease symptom, he said, "There is no lupus diet. There is only a healthy and a not healthy diet."

Living with lupus means a person also needs to be aware of the increased risks for other health problems, like cardiovascular disease, kidney disease and stroke.

Lupus can accelerate the process of atherosclerosis, the build up of plaque along the lining of arterial walls. Some people with lupus experience inflammation in the heart (myocarditis and endocarditis) or the surrounding membranes.

Having lupus can also increase your risk of infection, cancer,pregnancy complications andbone tissue death calledavascular necrosis

"I can't emphasize enough that lupus patients should be vaccinated for protection against infections before they are immunosuppressed," Caricchio said, adding that vaccines should not be given during a flare and that recombinant vaccines are the safest for them.

There are also consequences of treatment because of increased risk of side effects like diabetes and osteoporosis mostly from the prednisone, a corticosteroid. Caricchio said lupus patients should be monitored for these side effects and treated immediately to minimize complications.

Research is ongoing not only to identify better treatment options but also understand the disease's progression.

The Lupus Foundation of Americarecent foundthat more frequent flares is associated with worse patient hospitalization, and higher medical bills.

Another study points to arthritis, skin lesions and low, white blood cell counts as early signs of lupus. The researchers also found a strong auto-antibody presence in almost 90% of lupus patients.

Stem cell therapy is one of the newest treatments for lupus. Right now though it is still in clinical trials. Caricchio said that there are several new lupus treatments under investigation.

"I have been following lupus since the late 80s, and there has never been a better time for lupus clinical trials," he said. "Within two to three years, I anticipate that we will have more treatments to offer."

He also added, "Over the last 20 years, we have learned to better use what treatments we already have. Better experience with the medicines has helped us achieve many more remissions so patients can live longer, better quality lives."

See the original post:
Lupus can be difficult to diagnose because its symptoms mimic those of other illnesses - PhillyVoice.com

Cryo-Cell Confirms Specimen Longevity of 23+ Years with Optimal CD34 Viability – PR Web

Cryopreservation Tanks

OLDSMAR, Fla. (PRWEB) March 13, 2020

Cryo-Cell Internationals announcement is concurrent with the most recent research regarding the lifespan of stored cord blood performed by Dr. Hal Boxmeyer and colleagues, which determined sample viability of 23.5 years and suggested possible, indefinite length of storage time for cryogenically preserved cells under proper conditions. Cryo-Cell International marks the first family cord blood bank to release results concerning specimen viability for this length of time.

Since cord blood banking has only been in existence for 30 years, these findings indicate that specimen longevity nearly spans the lifetime of the industry. Research points to the idea that other cryogenically preserved cells remain undiminished by time, as long as cells are preserved at optimal storage temperature, where cellular activity is known to halt. Cryo-Cell International, Inc., stands as the only private use cord blood bank in the U.S. to receive the Foundation for the Accreditation for Cellular Therapy (FACT) accreditation, which addresses all quality aspects of cord blood collection, processing, testing, banking, selection and release of specimens.

Todd Schuesler, Director of Cryo-Cell Internationals laboratory and cryopreservation facility, noted, Cryo-Cell is accredited by FACT, AABB, and ISO13485, making us one of the most accredited cord blood banks in the U.S. These accreditations are only awarded to organizations with exceptional quality systems and acute commitment to customer care. Its our employees who make the difference; for many, it is personal, based on previous or current experiences with diseases that can or will potentially be treated with stem cells. Having access to cord blood and cord tissue for the treatment of diseases developed much later in life will prove to be invaluable as evolving research continues to reveal potential uses.

These are simply amazing results that validates our belief that, if properly processed and maintained at the proper temperature, cryogenically preserved cord blood stem cells can provide regenerative benefits for at least the babys lifetime and likely for generations thereafter, said David Portnoy, Cryo-Cell Internationals Chairman and Co-CEO. Currently, cord blood stem cells have been FDA-approved for standard treatment in nearly 80 diseases. Numerous clinical trials are underway to explore the use of umbilical stem cells in the treatment of various degenerative conditions, including autism and cerebral palsy.

About Cryo-Cell International, Inc.

Founded in 1989, Cryo-Cell International, Inc. is the world's first private cord blood bank. More than 500,000 parents from 87 countries trust Cryo-Cell to preserve their family members' stem cells. Cryo-Cell's mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine. Cryo-Cell operates in a facility that is FDA registered, cGMP-/cGTP-compliant, and is licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell is also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. In addition, Cryo-Cell is ISO 9001:2008 certified by BSI, an internationally recognized, quality assessment organization. Cryo-Cell is a publicly-traded company, OTCQB:CCEL. For more information, please visit http://www.cryo-cell.com. For a complete list of references, visit http://www.cryo-cell.com/references.

Forward-Looking Statement Statements wherein the terms "believes", "intends", "projects", "anticipates", "expects", and similar expressions as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company, which include future medical and research developments.The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.

Share article on social media or email:

Original post:
Cryo-Cell Confirms Specimen Longevity of 23+ Years with Optimal CD34 Viability - PR Web